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Effects of endothelin or angiotensin II receptor blockade on betic nephropathy [1]. Angiotensin-converting enzyme
diabetes in the transgenic (mRen-2)27 rat. (ACE) inhibitors and angiotensin type 1 receptor antag-
Background. Endothelin (ET) and angiotensin II (Ang II) onists (AT1) appear to be particularly effective in thisare vasoactive/trophic peptides that may contribute to the pro-
regard in both human and experimental diabetic nephrop-gression of diabetic nephropathy. The transgenic (mRen-2)27
athy [2–4]. Micropuncture studies have indicated thatrat exhibits overexpression of Ang II at sites of normal physio-
logical expression. Unlike other rat strains, the streptozotocin- renoprotection with these agents is associated with re-
induced diabetic Ren-2 rat develops progressive renal pathol- ductions in intraglomerular pressure [5, 6]. More recently,
ogy associated with a declining glomerular filtration rate (GFR) the induction of proinflammatory and prosclerotic growthand provides a convenient model to evaluate the role of these
factors by hyperglycemia [7–10] and possibly tubularvasoactive peptides in the nephropathic process.
protein load [11] have also been recognized as importantMethods and Results. Oral administration of either the endo-
thelin A (ETA) and ETB receptor antagonist bosentan or the contributors to the microvascular and tubulointerstitial
angiotensin type 1 (AT1) receptor antagonist valsartan for 12 pathology of diabetic renal disease [12]. In various exper-
weeks reduced systolic blood pressure (SBP) of nondiabetic
imental models of renal disease, including diabetes,and diabetic Ren-2 rats to normotensive levels. Diabetic renal
mRNA for transforming growth factor-b1 (TGF-b1) andpathology was associated with intense renin mRNA and pro-
tein in the proximal tubules and juxtaglomerular cells along collagen IV increases in the kidney with evidence that
with overexpression of transforming growth factor-b1 (TGF-b1) blockade of the renin-angiotensin system (RAS) de-
and collagen IV mRNA in glomeruli and tubules. With valsar- creases expression of these growth factors and matrix
tan but not bosentan, renin mRNA and protein in the proximal
proteins as well as renal pathology [12, 13]. This func-tubules were not detected. Valsartan but not bosentan reduced
tional interrelationship between angiotensin II (Ang II)TGF-b1 and collagen IV mRNA and the severity of diabetic
renal pathology. A declining GFR with diabetes was attenuated and TGF-b may represent an important trophic/profi-
by both treatments. Albuminuria in diabetic rats rose further brotic pathway involved in the progression of experimen-
with bosentan but was reduced with valsartan. tal diabetic nephropathy [14].Conclusions. Despite producing normotension, severe dia-
While the experimental streptozotocin (STZ)-inducedbetic renal pathology was not prevented by bosentan, sug-
diabetic rat develops proteinuria and modest expressiongesting dissociation of ET, albuminuria, and hypertension from
the structural injury in this diabetic model. The beneficial ef- of extracellular matrix (ECM), it is not associated with a
fects afforded by valsartan therapy strengthen the importance loss of renal function. In contrast, the diabetic transgenic
of the local renin-angiotensin system in mediating progressive (mRen-2)27 rats develop severe renal impairment anddiabetic renal injury.
histologic injury, which resembles human diabetic ne-
phropathy. In the transgenic (mRen-2)27 rat, the mouse
Ren-2 gene is inserted into the genome of a Sprague-The control of systemic and possibly intraglomerular
Dawley rat such that overexpression of renin occurs athypertension is a key factor in the management of dia-
sites of normal physiological expression [15]. This model
displays hypertension and develops progressive ne-
phropathy with the induction of STZ diabetes, possiblyKey words: glomerulosclerosis, renin-angiotensin system, endothelin,
diabetic nephropathy, hypertension. because of the activation of the intrarenal RAS [16], and
provides an opportunity to explore the relative impor-Received for publication June 8, 1999
tance of systolic blood pressure (SBP) versus the localand in revised form October 7, 1999
Accepted for publication November 17, 1999 RAS in the progression of diabetic nephropathy [16].
After an initial phase of hyperfiltration in the Ren-2Ó 2000 by the International Society of Nephrology
1882
Kelly et al: Nephropathy in the diabetic Ren-2 rat 1883
rat, STZ diabetes results in the rapid onset of renal units intraperitoneally; Ultratard, Novo Nordisk, Den-
impairment and severe renal pathology, with features mark) to promote weight gain and to reduce mortality.
similar to those observed in advanced human diabetic Experimental procedures adhered to the guidelines of
nephropathy. This progressive renal disease is prevented the National Health and Medical Research Council of
by ACE inhibitor treatment [16]. Australia’s Code for the Care and Use of Animals for
Endothelin (ET), a potent proinflammatory mediator, Scientific Purposes, and were approved by the Bioethics
has also been implicated in the progression of various Committee of the University of Melbourne.
renal pathologies [17]. ET has been shown to be elevated
Renal functional and biochemical studiesin the diabetic kidney [18], and ET antagonists have
been reported to reduce growth factor expression and Rats were individually housed in metabolic cages ev-
ECM accumulation in glomeruli from diabetic rats ery four weeks and habituated for two to three hours,
[18, 19]. Furthermore, ET antagonists ameliorate renal and measurements of fluid intake and urine excretion
pathology in several experimental models of kidney dis- rate were recorded over 24 hours. Animals continued to
ease [20, 21]. In the kidney, ET-1 mRNA is reduced by have free access to tap water and standard laboratory
ACE inhibition [19], and in vascular tissue, the effects chow during this period. After 24 hours in metabolic
of Ang II infusion are ameliorated by ET antagonism cages, an aliquot of urine (5 mL) was collected from the
[22]. Together, these studies suggest a functional interre- 24-hour urine sample and stored at 2708C for subse-
lationship between ET, Ang II, and structural injury. quent analysis of urinary electrolytes and albumin con-
Our current study compares an AT1 receptor antago- centration. Urinary Na1 and K1 concentrations and
nist with an ETA and ETB receptor antagonist at an equi- plasma electrolytes were measured in duplicate using an
potent antihypertensive dose to explore the relative automated IL 943 flame photometer (Instrumentation
involvement of Ang II and ET in mediating the renal Laboratories, Milan, Italy).
functional and structural abnormalities observed in the Albuminuria was determined by a double antibody
STZ diabetic Ren-2 rat. radioimmunoassay, as previously performed in our labo-
ratories [23]. The glomerular filtration rate (GFR) was
determined by injecting a single shot of 99Tc-DTPA intoMETHODS
the tail vein and sampling the blood after 43 minutes,Animals
as previously described [24].
Six-week-old female, heterozygous Ren-2 rats, weigh-
ing 125 6 5 g, were randomized to receive either 55 Plasma preparation
mg/kg of STZ (Sigma, St. Louis, MO, USA) diluted in
Prior to sacrifice, plasma samples (100 mL) were col-0.1 mol/L citrate buffer, pH 4.5, or citrate buffer alone
lected in heparinized vials (10 U/mL) from the tail vein(nondiabetic) by tail vein injection following an over-
of conscious rats. The blood samples were centrifugednight fast. Female rats were chosen because they do not
at 2000 3 g for five minutes at 48C, and the plasmarequire maintenance antihypertensive therapy. Diabetic
supernatant was removed and frozen for later estima-and nondiabetic Ren-2 (N 5 6 per group) were treated
tions of Na1 and K1.with an AT1 receptor antagonist, valsartan (average dose
of 20 mg/kg/day, in drinking water; Novartis, Basel, Swit- Anatomical studies
zerland), or the ET (ETA and ETB) receptor antagonist
Rats were anesthetized (Nembutal 60 mg/kg body wtbosentan (gavaged dose of 100 mg/kg/day; Roche, Basel,
intraperitoneally; Rhone Merieux, Pinkenba, QLD, Aus-Switzerland) for 12 weeks post-STZ or vehicle. Treat-
tralia), and the abdominal aorta was cannulated with anment commenced within 24 hours of STZ injection. All
18-gauge needle. Perfusion-exsanguination commencedrats were housed in a stable environment (maintained
at SBP (180 to 220 mm Hg) via the abdominal aortaat 22 6 18C with a 12-h light-day cycle) and allowed free
with 0.1 mol/L phosphate-buffered saline (PBS), pH 7.4access to tap water and standard rat chow containing
(20 to 50 mL), to remove circulating blood, and the0.25% Na1 and 0.76% K1 (GR2; Clark-King & Co.,
inferior vena cava adjacent to the renal vein was simulta-Gladesville, NSW, Australia). Each week, rats were
neously severed, allowing free flow of the perfusate.weighed, and blood glucose (nondiabetic, 4 to 8 mmol/L;
After clearance of circulating blood, 4% paraformalde-diabetic, 18 to 22 mmol/L) was determined using an
hyde in 0.1 mol/L phosphate buffer, pH 7.4, was perfusedAMES glucometer (Bayer Diagnostics, Melbourne, Aus-
for a further five minutes (100 to 200 mL of fixative) to fixtralia). Every four weeks, SBP was recorded in preheated
the tissues [25]. Kidneys were removed from the animal,conscious rats by tail cuff plethysmography. An average
decapsulated, and sliced transversely. Kidneys wereSBP reading was taken from three consecutive measure-
postfixed in the same fixative for two hours, routinelyments to reduce variability (Bunag 1973 ID: 572). Dia-
betic rats received a daily injection of insulin (2 to 4 processed, embedded in paraffin, and sectioned.
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Histopathology mouse and rat renin protein have been previously pub-
lished by our laboratory [25, 29]. The polyclonal mouseChanges in kidney structure were assessed in a blinded
renin protein antibody was raised against pure mouseprotocol in at least 25 randomly selected tissue sections
submandibular gland renin [25], and the polyclonal ratfrom each group studied. Sections were stained with
renin protein was raised in rabbits against a fusion pro-either Mayer’s hematoxylin and eosin (HE) to examine
tein that was incorporated into Escherichia coli [29].cell structure, periodic acid-Schiff stain (PAS) to identify
These antisera specifically label juxtaglomerular cells ofchanges in basement membrane architecture and glyco-
the kidney, zona glomerulosa cells of the adrenal, andgen deposition, or Masson’s modified trichrome to dem-
macroglial Mu¨ller cells of the retina. Renin protein anti-onstrate collagen matrix [26].
sera reveal the presence of both prorenin and partially
or fully processed active renin.Glomerulosclerotic index
From 3 mm kidney sections stained with PAS, 150 to In situ hybridization
200 glomeruli from rats were examined in a masked
The 1.4 kb cDNA probe for rat renin (gift of Dr. D.J.protocol. The degree of sclerosis in each glomerulus was
Campbell, Melbourne, Australia) was cloned into pGEMsubjectively graded on a scale of 0 to 4 by the method
4 (Stratagene, La Jolla, CA, USA) and linearized withof Saito et al: grade 0, normal; grade 1, sclerotic area up
Bam HI to produce an antisense riboprobe with T7 RNAto 25% (minimal); grade 2, sclerotic area 25 to 50%
polymerase. The 945 bp cDNA probe for TGF-b1 (gift(moderate); grade 3, sclerotic area 50 to 75% (moderate
of Dr. Qian, Bethesda, MD, USA) and the 600 bp cDNAto severe); and grade 4, sclerotic area 75 to 100% (severe)
probe for a1(IV) collagen (gift of Dr. R. Timpl, Mar-[27]. Glomerulosclerosis was defined as glomerular base-
tinsried, Germany) were also cloned into pBluescriptment membrane (GBM) thickening, mesangial hypertro-
KS1 (Stratagene) and linearized with XbaI and HindIII
phy, and capillary occlusion. A glomerulosclerotic index
to produce antisense riboprobes with T7 RNA polymer-
(GSI) was then calculated using the formula: ase. In situ hybridization was performed on 4 mm paraffin
sections, which were hybridized with antisense probesGSI 5 o
4
i50
Fi (i)
to renin, TGF-b1, and collagen IV [12]. Tissue sections
were dewaxed in histosol, hydrated through graded etha-
where Fi is the percentage of glomeruli in the rat with nol, and immersed in distilled water. Sections were then
a given score (i). washed in 0.1 mol/L PBS, pH 7.4, and hybridized with
33P-labeled antisense and sense-specific probes (5 3 105Immunohistochemistry
cpm/25 mL hybridization buffer), which were added to
Three micron sections were placed into histosol to hybridization buffer (300 mmol/L NaCl, 10 mmol/L Tris-
remove the paraffin wax, hydrated in graded ethanol, HCl, pH 7.5, 10 mmol/L Na2HPO4, pH 6.8, 5 mmol/L
and immersed into tap water before being incubated for ethylenediaminetetraacetic acid (EDTA), pH 8.0, 1 3
20 minutes with normal goat serum (NGS) diluted 1:10 Denhardt’s solution, 0.8 mg yeast RNA/mL, 50% deion-
with 0.1 mol/L PBS, pH 7.4. Sections were then incubated ized formamide, and 10% dextran sulfate), heated to
for 18 hours at 48C with specific primary antisera to renin 858C and 25 mL added to the sections. Cover slips were
protein. Sections incubated with 1:10 NGS instead of the placed on the sections, and the slides were incubated in
primary antiserum served as the negative control. After a humidified chamber (50% formamide) at 608C for 14
thorough washing with PBS (3 3 5 min changes), the to 16 hours. Slides were then washed in 2 3 standard
sections were flooded with a solution of 5% hydrogen saline citrate (SSC; 0.3 mol/L NaCl, 0.33 mol/L Na3-
peroxide, rinsed with PBS (2 3 5 min), and incubated C6H5O712H2O) containing 50% formamide at 508C to
with biotinylated goat antirabbit IgG (Dakopatts, Glo- remove the cover slips. The slides were again washed
strup, Denmark) diluted 1:200 with PBS. Sections were with 2 3 SSC, 50% formamide for a further one hour
rinsed with PBS (2 3 5 min) and incubated with an at 558C. Sections were then rinsed three times in RNase
avidin-biotin peroxidase complex (Vector, Burlingame, buffer (10 mmol/L Tris-HCl, pH 7.5, 1 mmol/L EDTA,
CA, USA) diluted 1:200 with PBS. Following rinsing pH 8.0, 0.5 mol/L NaCl) at 378C and treated with 150 g
with PBS (2 3 5 min), sections were incubated with RNase A/mL in RNnase buffer for a further one hour
0.05% diaminobenzidine and 0.05% hydrogen peroxide at 378C and then washed with 2 3 SSC at 558C for
(Pierce, Rockford, IL, USA) in PBS, pH 7.6, for one 45 minutes. Finally, sections were dehydrated through
to three minutes, rinsed in tap water for five minutes, graded ethanol, air dried, and exposed to Kodak X-Omat
counterstained in Mayer’s hematoxylin, differentiated in Autoradiography film for four days at room temperature.
Scott’s tap water, dehydrated, cleared, and mounted in Slides were coated with Ilford K5 emulsion (Ilford, 1:1
Depex [28]. with distilled water), stored with desiccant at room tem-
perature for 21 days, developed in Kodak D19, fixed inThe nature and specificities of the antisera raised to
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Table 1. Body weight, systolic blood pressure, and plasma glucose of nondiabetic and diabetic transgenic (mRen-2)27 treated for 12 weeks
with either valsartan or bosentan
Plasma mmol/L Urine lmol/min
Body weight Systolic BP
g mm Hg Glucose Na1 K1 Na1 K1
Nondiabetic 29169 21969 5.260.3 14063 4.460.2 1.3160.3 2.3760.4
Nondiabetic 1 V 30167 13366c 6.360.5 14163 4.060.2 1.0460.2 1.8260.2
Nondiabetic 1 B 33267 13964c 5.960.6 13864 4.060.2 1.1860.1 2.0360.5
Diabetic 21868b 23166 21.760.9b 14362 6.860.3a 2.6460.4a 4.4360.4a
Diabetic 1 V 243614b 13467c 21.460.7b 14064 4.760.2a 3.3060.5a 7.2360.7a,c
Diabetic 1 B 249614b 12967c 19.660.6b 14164 5.460.2a 2.6160.57a 3.3760.71a
Values are expressed as means 6 SEM; N 5 6 rats per group. Abbreviations are: V, valsartan; B, bosentan.
aP , 0.05 when compared with respective nondiabetic rats
bP , 0.01 when compared with respective nondiabetic rats
cP , 0.05 when compared with respective untreated rats
Table 2. Albuminuria and glomerular filtration rate in nondiabeticIlford Hypam, and stained with HE. For quantitation of
and diabetic transgenic (mRen-2)27 rats treated for 12 weeks with
in situ hybridization, images of kidney sections were either valsartan or bosentan
captured and digitized using a Fujix HC-2000 digital cam-
Albuminuria GFR
era (Fuji, Tokyo, Japan). Regional gene expression was mg/24 h mL/min
quantitatively measured using an image analysis system
Nondiabetic 0.3060.10 3.3560.1
(AIS Imaging, Ontario, Canada), whereby the propor- Nondiabetic 1 V 0.4260.08b 3.2160.1
Nondiabetic 1 B 2.9060.88b 3.6460.2tional area occupied by autoradiographic grains was
Diabetic 2.4260.20a 1.5660.1ameasured against the total area of section from a mini- Diabetic 1 V 1.2060.10a,b 2.4560.1a,b
mum of three sections per animal (N 5 6 animals per Diabetic 1 B 6.1760.4a,b 2.3260.1a,b
group), as previously described [30]. Values are expressed as means 6 SEM; N 5 6 rats per group. V, valsartan;
B, bosentan; GFR, glomerular filtration rate.
aP , 0.05 when compared with respective nondiabetic ratsStatistics bP , 0.05 when compared to respective untreated rats
Data are expressed as means 6 SEM unless otherwise
stated. Statistical significance was determined by a two-
way analysis of variance (ANOVA) with a Fishers post
played the largest increase in urinary electrolyte outputhoc comparison. Albuminuria was analyzed using log
(P , 0.05; Table 1).transformed data and a represented as geometric means
Renal parameters. Diabetes was associated with an
3/4 tolerance factors. Analyses were performed using
increase in urinary albumin excretion. Bosentan treat-Statview II 1 Graphics package (Abacus Concepts,
ment increased albumin excretion further in both nondi-
Berkeley, CA, USA) on an Apple Macintosh G3 com-
abetic and diabetic rats, while valsartan treatment was
puter (Apple Computer, Inc., Cupertino, CA, USA). A associated with reduced albumin excretion in diabetic
P value , 0.05 was regarded as statistically significant. rats (Table 2). The impairment in GFR observed in dia-
betic Ren-2 rats was attenuated by all treatment regi-
mens, although the GFR was still significantly lower thanRESULTS
the respective drug-treated nondiabetic rats (Table 2).Renal functional and biochemical studies
Body weight, systolic blood pressure and plasma glu- Anatomical studies
cose. Diabetic rats had reduced body weight indepen- In the kidney cortex of nondiabetic rats, there was
dent of treatment (P , 0.01). SBP was decreased to a no significant renal pathology (Fig. 1A). However, in
similar level within one week of commencement of either diabetic rats, most glomeruli displayed thickened GBM,
valsartan or bosentan in diabetic rats (P , 0.01; Table mesangial expansion, and capillary occlusion, as well as
1). Plasma glucose was elevated to a similar extent in all efferent arteriole hyalinization and tubular vacuolation
diabetic rat groups, independent of treatment (P , 0.01; (Fig. 1B). In both nondiabetic and diabetic rats treated
Table 1). with valsartan (Fig. 1 C, D) and nondiabetic rats treated
Plasma and urinary electrolytes. In drug-treated dia- with bosentan (Fig. 1E), only minimal evidence of GBM
betic rats, plasma K1 was increased compared with drug- thickening was apparent. Diabetic rats treated with bo-
treated nondiabetic controls (P , 0.05). Urinary electro- sentan (Fig. 1F) displayed severe glomerulosclerosis and
lyte excretion was increased in diabetic rats, irrespective tubulointerstitial disease.
In the medulla of nondiabetic and diabetic rats treatedof drug treatment. Valsartan-treated diabetic rats dis-
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Fig. 1. Histopathology of the kidney cortex in non-diabetic and diabetic transgenic (mRen-2)27 treated for 12 weeks with either valsartan or bosentan.
Sections are stained with PAS. G, glomerulus. (A) In nondiabetic rats, there is minimal evidence of glomerulosclerosis. (B) Diabetic rats have
severe glomerulosclerosis, arteriolar hyalinization (*). Valsartan-treated nondiabetic (C ) and diabetic rats (D) and bosentan-treated nondiabetic
rats (E ) have minimal evidence of glomerulosclerosis. Bosentan-treated diabetic rats (F ) have severe glomerulosclerosis and cortical interstitial
fibrosis (arrow, magnification 3300). Reproduction of this figure in color was made possible by Novartis Pharmaceuticals, Bern, Switzerland.
with valsartan (Fig. 2 C, D) and nondiabetic rats treated rats treated with either valsartan or bosentan (data not
shown) and diabetic rats treated with valsartan displayedwith bosentan (Fig. 2E), there was no evident pathology.
However, in diabetic rats (Fig. 2B) and diabetic rats labeling for renin mRNA (Fig. 3C) and protein (Fig.
4C) in JGA only. Diabetic rats treated with bosentantreated with bosentan (Fig. 2F), there was florid deposi-
tion of collagen matrix, tubular dilation and degenera- displayed intense labeling for renin mRNA (Fig. 3D)
and protein (Fig. 4D) in both JGA and proximal tubules.tion, and the presence of inflammatory cells.
Renin mRNA and immunohistochemistry Transforming growth factor-b1 and collagen IV mRNA
In nondiabetic rats, TGF-b1 (Fig. 5 A, B) and collagenIn nondiabetic rats, some juxtaglomerular apparatuses
(JGAs) were positive for renin mRNA (Fig. 3A) or pro- IV (Fig. 6 A, B) mRNA were barely detected in the
kidney, while in diabetic rats, TGF-b1 (Fig. 5 C, D) andtein (Fig. 4A), whereas with diabetes, most JGAs and
proximal tubules displayed intense labeling for renin collagen IV (Fig. 6 C, D) mRNA were increased (Fig.
7) and associated with sclerotic glomeruli and regions ofmRNA (Fig. 3B) and protein (Fig. 4B). Nondiabetic
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Fig. 2. Histopathology of the kidney medulla in nondiabetic and diabetic transgenic (mRen-2)27 treated for 12 weeks with either valsartan or bosentan.
Sections are stained with Masson’s Trichrome. VR, vasa recta. (A) Nondiabetic rats have no evidence of medullary pathology, whereas (B) diabetic
rats have dilated tubules, degenerated vasa recta bundles, and the presence of inflammatory cells (arrow), and there appeared to be more collagen
(stained blue). In valsartan-treated nondiabetic (C ) and diabetic rats (D) and bosentan-treated nondiabetic rats (E ), there is no evidence of
medullary pathology. Bosentan-treated diabetic rats (F ) have dilated tubules, degenerated vasa recta bundles and the presence of inflammatory
cells (arrow), and there appears to be more collagen (stained blue) throughout the interstitium (magnification 3300). Reproduction of this figure
in color was made possible by Novartis Pharmaceuticals, Bern, Switzerland.
tubulointerstitial disease. In valsartan-treated nondia- nificantly lower than in diabetic rats (P , 0.05; Table
betic (not shown) and diabetic rats, the levels of TGF-b1 3). The GSI in diabetic rats treated with bosentan was
(Fig. 5 E, F) and collagen IV (Fig. 6 E, F) mRNA were not significantly reduced when compared with diabetic
similar to nondiabetic rats (Fig. 7). In bosentan-treated rats (Table 3), but there were fewer severely sclerotic
nondiabetic rats, both TGF-b1 and collagen IV mRNA glomeruli.
(data not shown) were similar to nondiabetic rats (Fig.
7). In diabetic rats treated with bosentan, TGF-b1 (Fig.
DISCUSSION5 G, H), and collagen IV (Fig. 6 G, H), mRNA was
Blockade of the RAS with AT1 antagonists or ACElocalized to glomeruli and areas of tubulointerstitial dis-
inhibitors has been shown previously to improve glomer-ease, similar to that seen in diabetic rats (Fig. 7).
ular hemodynamics and structure in human and rodent
Glomerulosclerotic index diabetic nephropathy [2, 4, 5, 31, 32]. The present findings
provide further evidence for a direct causal relationshipDiabetes was associated with an increase in the GSI.
The GSI in diabetic rats treated with valsartan was sig- between the activity of the intrarenal RAS and the pro-
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Fig. 3. Renin mRNA of the kidney in nondiabetic and diabetic transgenic (mRen-2)27 treated for 12 weeks with either valsartan or bosentan.
Sections are stained with HE. (A) Nondiabetic rats displayed renin mRNA (arrow) in the JGA, whereas in (B) rats with diabetes there was intense
renin mRNA (arrow) in both the JGA and the proximal tubules. In diabetic rats treated with valsartan (C ), renin mRNA (arrow) was detected
in the JGA only. In diabetic rats treated with bosentan (D), gene expression for renin mRNA (arrow) was present in both JGA and the cytoplasm
of proximal tubules (magnification 3300). Reproduction of this figure in color was made possible by Novartis Pharmaceuticals, Bern, Switzerland.
gression of diabetic nephropathy. As with ACE inhibi- present study, hypertension in the Ren-2 rat appeared to
be partly ET dependent, yet blockade of the ET receptortion in our previous study [16], treatment with the AT1
antagonist valsartan reduced SBP, ameliorated the se- failed to attenuate the diabetic renal pathology. There-
fore, it appears that the vasoconstrictor effects of hor-vere pathology, and improved the renal function of dia-
betic Ren-2 rats (Table 4). By contrast, bosentan, al- mones such as ET and Ang II can be functionally sepa-
rated from their actions in the microvascular tissues.though normalizing blood pressure and improving GFR,
had little or no effect on the florid renal pathology and Indeed, agents such as AT1 antagonists or ACE inhibi-
tors can confer renoprotective benefits without majorwas associated with increased albuminuria (Table 4).
Bosentan reduced SBP to normotensive levels in both effects of systemic blood pressure, as has been observed
in studies performed in normotensive diabetic rats [3].nondiabetic and diabetic Ren-2 rats, suggesting that the
hypertension of this Ren-2 strain is ET dependent. These Despite only a modest reduction in SBP, agents that
interrupt the RAS confer renoprotection in diabetes [5].findings are in accordance with other investigators who
have shown that the hypertension in the Ren-2 rat is The possibility of renoprotection independent of effects
on SBP with agents that interrupt the RAS has alsoprobably mediated by locally generated Ang II and ET
[33]. This is in accordance with experimental data, which been suggested in a range of clinical studies of diabetic
nephropathy [4].have shown that the chronic pressor properties of infused
Ang II in normal rats are blunted by bosentan [34]. In the The finding that bosentan did not reduce renal pathol-
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Fig. 4. Renin immunohistochemistry of the kidney in nondiabetic and diabetic transgenic (mRen-2)27 treated for 12 weeks with either valsartan
or bosentan. Sections are counterstained with Mayer’s hematoxylin. G, glomerulus. (A) Nondiabetic rats displayed renin protein (arrow) in the
JGA, whereas with (B) diabetic animals there was intense renin protein (arrow) in both the JGA and the proximal tubules. (C ) In diabetic rats
treated with valsartan, renin protein (arrow) was detected in the JGA only. (D) In diabetic rats treated with bosentan, renin protein (arrow) was
detected in both the JGA and the cytoplasm of proximal tubules (magnification 3300).
ogy in the diabetic Ren-2 contrasts with other reports This may explain the improvement in GFR in diabetic
Ren-2 rats treated with bosentan. A discrepancy betweenof both hemodynamic and pathological benefits with the
ET blockade in various forms of renal disease [20, 21]. the effects of ET receptor antagonism on glomerular
function and structural injury has also been reportedIn other models of experimental diabetes, treatment with
another nonselective ET antagonist has reduced both in a model of cyclosporine nephrotoxicity [36]. Other
investigators have shown a correlation between GFRalbuminuria and SBP [21], whereas in the present study,
ET antagonism decreased SBP but increased albumin- and occluded glomeruli in diabetes [37, 38]. This im-
provement in renal function could relate to the knownuria. One must be cautious when comparing the two
studies since the present studies were performed in trans- beneficial effects of bosentan on glomerular and systemic
hemodynamics [39]. ET-1 has been reported to increasegenic rats that develop renal failure. In the diabetic
Ren-2 rat, it is possible that the disease is predominantly intraglomerular pressure with ET blockade lowering glo-
merular pressure [40]; however, this is not a universalAng II dependent, although kidney and plasma Ang II
levels actually decrease with diabetes [35]. The results finding, as a study found that ET can reduce intraglomer-
ular pressure, albeit at high doses [41]. ET-1 inducesof the present study suggest that local cell-specific auto-
crine/paracrine mechanisms may be more relevant than mesangial cell contraction [42], and therefore, ET block-
ade would be expected to increase the glomerular filtra-whole tissue peptide levels. Indeed, in the present study,
there was evidence of a local increase in renin in proximal tion surface area through mesangial cell relaxation. This
effect on the glomerular barrier may explain the in-tubules of diabetic rat kidneys consistent with specific
activation of the RAS within the kidney. creased albuminuria associated with bosentan in the
Ren-2 rats, irrespective of the presence of diabetes. SinceAlthough bosentan did not improve the overall GSI,
there were significantly fewer severely sclerotic (grades albumin occurs as a result not only of the glomerulus
but also tubular factors, one cannot exclude the effects3 and 4) glomeruli when compared with untreated rats.
Fig. 5. Transforming growth factor-b1 mRNA in the kidney in nondiabetic and diabetic transgenic (mRen-2)27 treated for 12 weeks with either
valsartan or bosentan. Sections were stained with HE. (A, C, E, and G ) Bright-field micrographs. (B, D, F, and H ) Corresponding dark-field
micrographs. In both nondiabetic (A and B) and diabetic (E and F) rats treated with valsartan, there was minimal gene expression for TGF-b1
detected. However, in both diabetic (C and D) and diabetic rats treated with bosentan (G and H), there was intense gene expression for TGF-b1
in the glomerulus (G) and regions of tubulointerstitial injury (magnification 3300).
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Fig. 6. Collagen IV mRNA in the kidney in nondiabetic and diabetic transgenic (mRen-2)27 treated for 12 weeks with either valsartan or bosentan.
Sections were stained with HE. (A, C, E, and G) Bright-field micrographs. (B, D, F, and H) Corresponding dark-field micrographs. In both nondiabetic
(A and B) and diabetic rats treated with valsartan (E and F), there was minimal gene expression for collagen IV detected. However, in both
diabetic (C and D) and diabetic rats treated with bosentan (G and H), there was intense gene expression for collagen IV in the glomerulus (G)
and regions of tubulointerstitial injury (magnification 3600).
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Fig. 7. Quantitation of gene expression for TGF-b1 (A) and collagen IV (B). Values are expressed as means 6 SEM (N 5 6). *P , 0.05 when
compared with respective nondiabetic rats; #P , 0.05 when compared with untreated diabetic rats.
Table 3. Glomerulosclerotic index and the percentage of glomerulosclerosis in kidneys from nondiabetic and diabetic transgenic
(mRen-2)27 rats treated for 12 weeks with either valsartan or bosentan
%
GSI Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Nondiabetic 0.8060.10 4465 2964 2463 361 0
Nondiabetic 1 V 0.2460.06b 7666 2466 0 0 0
Nondiabetic 1 B 0.4260.18 67612 2569 663 260.6 0
Diabetic 1.7560.10a 1967 2462 2862 21 63a 862a
Diabetic 1 V 1.0760.21a,b 21610 52611 1565 10 66a,b 261a,b
Diabetic 1 B 1.6060.3a 3066 3965 2062 8.763a,b 2.360.7a,b
Values are expressed as means 6 SEM; N 5 6 rats per group.
aP , 0.05 when compared with respective nondiabetic rats
bP , 0.05 when compared with respective untreated rats
Table 4. Summary of results
Control Diabetic Diabetic (V) Diabetic (B)
SBP ! ! ## ##
Albuminuria ! " # ""
Serum K1 ! " ! "
GFR ! ## # #
Histopathology
Cortex ! "" " ""
Medulla ! "" ! ""
Renin mRNA
JGA ! "" "" "
PCT N/D "" N/D ""
Renin protein
JGA ! "" "" "
PCT N/D "" N/D ""
TGF-b1 mRNA ! "" ! ""
Collagen IV mRNA ! "" ! ""
Abbreviations are: V, valsartan; B, bosentan; GFR, glomerular filtration rate; SBP, systolic blood pressure; JGA, juxtaglomerular cells; PCT, proximal tubules;
ND, not detected.
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donation of the transgenic rats required to establish our existing colony,of ET antagonists on tubular reabsorption of albumin,
and Ms. Bronwyn Rees and Mr. Matthew Waldron for expert technical
an area not previously investigated in detail. assistance. Reproduction of Figures 1 to 3 in color was made possible
by Novartis Pharmaceuticals, Bern, Switzerland.We have previously hypothesized from findings with
the ACE inhibitor perindopril in this model that the
Reprint requests to Darren J. Kelly, Ph.D., Department of Medicine,
appearance of renin in proximal tubules represents a Austin and Repatriation Medical Center (Repatriation Campus), Heidel-
berg West, Victoria, Australia, 3081.potential pathogenic mechanism for tubulointerstitial
E-mail: dkelly@austin.unimelb.edu.audisease [16]. As with perindopril, valsartan treatment of
diabetic Ren-2 prevented the appearance of renin in
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